Maculopapular eruptions associated to COVID-19 : A subanalysis of the COVID-Piel study
© 2020 Wiley Periodicals LLC..
A previous study has defined the maculopapular subtype of manifestations of COVID-19. The objective of our study was to describe and classify maculopapular eruptions associated with COVI-19. We carried out a subanalysis of the maculopapular cases found in the previous cross-sectional study. Using a consensus, we defined seven clinical patterns. We described patient demographics, the therapy received by the patient and the characteristics of each pattern. Consensus lead to the description of seven major maculopapular patterns: morbilliform (45.5%), other maculopapular (20.0%), purpuric (14.2%), erythema multiforme-like (9.7%), pytiriasis rosea-like (5.7%), erythema elevatum diutinum-like (2.3%), and perifollicular (2.3%). In most cases, maculopapular eruptions were coincident (61.9%) or subsequent (34.1%) to the onset of other COVID-19 manifestations. The most frequent were cough (76%), dyspnea (72%), fever (88%), and astenia (62%). Hospital admission due to pneumonia was frequent (61%). Drug intake was frequent (78%). Laboratory alterations associated with maculo-papular eruptions were high C-reactive protein, high D-Dimer, lymphopenia, high ferritin, high LDH, and high IL-6. The main limitation of our study was the impossibility to define the cause-effect relationship of each pattern. In conclusion, we provide a description of the cutaneous maculopapular manifestations associated with COVID-19. The cutaneous manifestations of COVID-19 are wide-ranging and can mimic other dermatoses.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
Dermatologic therapy - 33(2020), 6 vom: 30. Nov., Seite e14170 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Català, Alba [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral Agents |
|---|
| Anmerkungen: |
Date Completed 13.01.2021 Date Revised 12.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/dth.14170 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM313541728 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM313541728 | ||
| 003 | DE-627 | ||
| 005 | 20231225150811.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/dth.14170 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1045.xml |
| 035 | |a (DE-627)NLM313541728 | ||
| 035 | |a (NLM)32779280 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Català, Alba |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Maculopapular eruptions associated to COVID-19 |b A subanalysis of the COVID-Piel study |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.01.2021 | ||
| 500 | |a Date Revised 12.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 Wiley Periodicals LLC. | ||
| 520 | |a A previous study has defined the maculopapular subtype of manifestations of COVID-19. The objective of our study was to describe and classify maculopapular eruptions associated with COVI-19. We carried out a subanalysis of the maculopapular cases found in the previous cross-sectional study. Using a consensus, we defined seven clinical patterns. We described patient demographics, the therapy received by the patient and the characteristics of each pattern. Consensus lead to the description of seven major maculopapular patterns: morbilliform (45.5%), other maculopapular (20.0%), purpuric (14.2%), erythema multiforme-like (9.7%), pytiriasis rosea-like (5.7%), erythema elevatum diutinum-like (2.3%), and perifollicular (2.3%). In most cases, maculopapular eruptions were coincident (61.9%) or subsequent (34.1%) to the onset of other COVID-19 manifestations. The most frequent were cough (76%), dyspnea (72%), fever (88%), and astenia (62%). Hospital admission due to pneumonia was frequent (61%). Drug intake was frequent (78%). Laboratory alterations associated with maculo-papular eruptions were high C-reactive protein, high D-Dimer, lymphopenia, high ferritin, high LDH, and high IL-6. The main limitation of our study was the impossibility to define the cause-effect relationship of each pattern. In conclusion, we provide a description of the cutaneous maculopapular manifestations associated with COVID-19. The cutaneous manifestations of COVID-19 are wide-ranging and can mimic other dermatoses | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a coronavirus | |
| 650 | 4 | |a cutaneous manifestations | |
| 650 | 4 | |a skin | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Galván-Casas, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Carretero-Hernández, Gregorio |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez-Jiménez, Pedro |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández-Nieto, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez-Villa, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Navarro-Fernández, Íñigo |e verfasserin |4 aut | |
| 700 | 1 | |a Ruiz-Villaverde, Ricardo |e verfasserin |4 aut | |
| 700 | 1 | |a Falkenhain-López, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Llamas-Velasco, Mar |e verfasserin |4 aut | |
| 700 | 1 | |a Carnero-Gonzalez, Lucía |e verfasserin |4 aut | |
| 700 | 1 | |a García-Gavin, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Baniandrés, Ofelia |e verfasserin |4 aut | |
| 700 | 1 | |a González-Cruz, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Morillas-Lahuerta, Víctor |e verfasserin |4 aut | |
| 700 | 1 | |a Cubiró, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Figueras, Ignasi |e verfasserin |4 aut | |
| 700 | 1 | |a Selda-Enriquez, Gerald |e verfasserin |4 aut | |
| 700 | 1 | |a Fustà-Novell, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Roncero-Riesco, Mónica |e verfasserin |4 aut | |
| 700 | 1 | |a Burgos-Blasco, Patrícia |e verfasserin |4 aut | |
| 700 | 1 | |a Romaní, Jorge |e verfasserin |4 aut | |
| 700 | 1 | |a Solà-Ortigosa, Joaquim |e verfasserin |4 aut | |
| 700 | 1 | |a García-Doval, Ignacio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Dermatologic therapy |d 1998 |g 33(2020), 6 vom: 30. Nov., Seite e14170 |w (DE-627)NLM096394870 |x 1529-8019 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2020 |g number:6 |g day:30 |g month:11 |g pages:e14170 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/dth.14170 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2020 |e 6 |b 30 |c 11 |h e14170 | ||